活化凝血因子XI活性升高对急性静脉血栓栓塞症的预测价值
该研究在321例急性静脉血栓栓塞症(VTE)患者和300例无VTE史的人群对照中检测接触激活指标,发现患者FXIa:α1AT、FXIa:AT及PKa:C1-inh水平升高,FXIa:α1AT和FXIa:C1-inh对2年复发VTE或死亡有显著预后价值,提示FXIa抑制在急性VTE中可能有用。
要点
- 急性VTE患者FXIa:α1AT、FXIa:AT和PKa:C1-inh水平高于对照。
- FXI:c和FXIa:α1AT对急性VTE有良好判别价值,AUC分别为0.64和0.73。
- 基线FXIa:α1AT和FXIa:C1Inh对2年复发VTE或死亡有显著预后价值。
核心结论
- 急性VTE中FXIa水平和活性升高,且与复发VTE相关,提示FXI激活对VTE有重要风险贡献。
- 研究证据支持FXIa抑制在急性VTE setting中的效用。
研究设计与样本
- 研究纳入急性VTE患者321例和无VTE史的人群对照300例,检测血浆FXI(a)水平、活性及PKa活性。
主要发现
- 患者FXI:c水平为124 ± 37%,对照为114 ± 28%;患者校准自动血栓图FXIa水平较低。
- 患者FXIa:α1AT为312pM(238-424),对照为203pM(144-288);FXIa:AT为29pM(23-38) vs 23pM(20-30);PKa:C1-inh为1.9nM(1.2-4.7) vs 1.4nM(0.7-3.5)。
- FXIa:C1-inh水平两组无差异。
- FXI:c和FXIa:α1AT的AUC分别为0.64(0.6/0.69)和0.73(0.69/0.77)。
- 2年随访中患者队列发生81例复发VTE或死亡,基线FXIa:α1AT的HR为1.26(95%CI 1.10-1.45;p=.0012),FXIa:C1Inh的HR为1.19(95%CI 1.05-1.36;p=.0082)。
关键数值与推荐
- FXIa:α1AT每增加1个SD,复发VTE或死亡风险HR为1.26(95%CI 1.10-1.45;p=.0012)。
- FXIa:C1Inh每增加1个SD,复发VTE或死亡风险HR为1.19(95%CI 1.05-1.36;p=.0082)。
临床怎么用
- 作者认为研究证据支持FXIa抑制在急性VTE setting中的效用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) is associated with excessive coagulation activity, which in part can be attributed to activation of contact system. However, the knowledge regarding the impact of contact activation in acute VTE is limited. OBJECTIVE: To unravel the involvement of contact activation in acute VTE. METHODS: Contact activation was investigated in patients with acute VTE (n = 321) and population controls without a history of VTE (n = 300). For comparison, Factor XI(a) levels, activity, and plasma kallikrein (PKa) activity were determined in plasma samples with an activated partial thromboplastin time- or thrombin generation-based assay (free FXI concentration [FXI:c] and calibrated automated thrombogram:FXIa, respectively) and with enzyme-linked immunosorbent assays for enzyme-inhibitor complexes (FXIa:alpha-1-antitrypsin [α1AT], FXIa:antithrombin [AT], FXIa:C1-inhibitor [C1Inh], and PKa:C1-inh). RESULTS: In patients with VTE, higher FXI:c levels (124 ± 37% vs 114 ± 28%), but lower calibrated automated thrombogram:FXIa levels were apparent. This was accompanied by increased FXIa:α1AT, FXIa:AT, and PKa:C1-inh levels in patients compared with controls (312pM [238-424] vs 203pM [144-288]; 29pM [23-38] vs 23pM [20-30]; 1.9nM [1.2-4.7] vs 1.4nM [0.7-3.5], respectively), whereas FXIa:C1-inh levels did not differ. Logistic regression models showed good discriminatory values for FXI:c and FXIa:α1AT (area under the curve = 0.64 [0.6/0.69] and 0.73 [0.69/0.77], respectively). After a 2-year follow-up, 81 recurrent VTE events or deaths occurred in the patient cohort, for which the baseline levels of FXIa:α1AT and FXIa:C1Inh had a significant prognostic value (Hazard ratios per SD [95% CI], 1.26 [1.10-1.45]; p =.0012 and 1.19 [1.05-1.36]; p =.0082, respectively). CONCLUSION: Our study revealed elevated FXIa levels and activity in acute VTE, which was also associated with recurrent VTE, suggesting an important risk contribution of FXI activation to VTE. The evidence provided by this study supports the utility of FXIa inhibition in the setting of acute VTE.
引用
- Nagy M, Robles AP, Visser M, et al. Predictive value for increased activated factor XI activity in acute venous thromboembolism. J Thromb Haemost. 2023. PMID: 37003466. doi:10.1016/j.jtha.2023.02.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。